This article is more than 5 years old. Information may no longer be current.

Roche acquires ForSight Vision4

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Roche Holdings Inc. has acquired ForSight Vision4, a developer of retinal disease drug delivery technology, according to a press release from ForSight Vision4.

ForSight Vision4 previously entered a collaboration and license agreement for rights to its proprietary drug delivery technology for VEGF-A with Genentech, a member of the Roche Group.

“This transaction marks the successful culmination of an early and ongoing collaboration between the ForSight Vision4 team and the team at Genentech, and puts the PDS technology on a path to revolutionize retinal therapies for patients worldwide,” K. Angela Macfarlane, president and CEO of ForSight Vision4, said in the release.

Roche acquired the company for an undisclosed upfront sum and earn-out payments based on development and commercial milestones, the release said.